Office of Research on Women's Health, National Institutes of Health, Bethesda, Maryland.
Synergy Enterprises, Inc., Silver Spring, Maryland.
J Womens Health (Larchmt). 2020 Jun;29(6):858-864. doi: 10.1089/jwh.2019.8247. Epub 2020 Jan 22.
A little over 5 years ago, the U.S. National Institutes of Health (NIH) announced the intention to develop policies to require applicants to report plans to balance male and female cells and animals in preclinical investigations. Soon thereafter, the NIH issued a request for information from the scientific community and consulted with various stakeholders. The feedback received was considered during development of policy requiring the consideration of sex as a biological variable (SABV) in NIH-funded research on vertebrate animals and humans, which went into effect for applications due on or after January 25, 2016. We identified NIH programs related to SABV and reviewed SABV-relevant scientific literature. We find that the application of SABV throughout the research process can serve as a guiding principle to improve the value of biomedical science. The NIH is engaged in ongoing efforts to develop resources to help investigators consider SABV in their research. We also provide an update on lessons learned, highlight ways that different disciplines consider SABV, and describe the opportunities for scientific discovery that applying SABV offers. We call on NIH's various stakeholders to redouble their efforts to integrate SABV throughout the biomedical research enterprise. Sex- and gender-aware investigations are critical to the conduct of rigorous and transparent science and the advancement of personalized medicine. This kind of research achieves its greatest potential when sex and gender considerations are integrated into the biomedical research enterprise in an end-to-end manner, from basic and preclinical investigations, through translational and clinical research, to improved health care delivery.
大约 5 年前,美国国立卫生研究院 (NIH) 宣布打算制定政策,要求申请人在临床前研究中报告平衡男性和女性细胞和动物的计划。此后不久,NIH 向科学界征求意见,并与各利益攸关方进行了磋商。在制定要求在 NIH 资助的脊椎动物和人类研究中考虑性别作为生物变量 (SABV) 的政策时,考虑了收到的反馈意见,该政策于 2016 年 1 月 25 日或之后提交的申请生效。我们确定了与 SABV 相关的 NIH 计划,并审查了与 SABV 相关的科学文献。我们发现,在整个研究过程中应用 SABV 可以作为提高生物医学科学价值的指导原则。NIH 正在不断努力开发资源,帮助研究人员在其研究中考虑 SABV。我们还提供了经验教训的更新,强调了不同学科考虑 SABV 的方式,并描述了应用 SABV 带来的科学发现机会。我们呼吁 NIH 的各种利益攸关方加倍努力,将 SABV 纳入整个生物医学研究企业。关注性别和性别的调查对于进行严格和透明的科学以及推进个性化医学至关重要。当从基础和临床前研究到转化和临床研究,再到改善医疗保健服务,全面考虑性别和性别的因素,将其纳入生物医学研究企业时,这种研究才能发挥最大潜力。